Publications
Efficacy and safety of topical sofpironium bromide gel for the treatment of axillary hyperhidrosis: A phase II, randomized, controlled, double-blinded trial
Brandon Kirsch MD, Stacy Smith MD, Joel Cohen MD, Janet DuBois MD Lawrence Green MD. Leslie Baumann MD. Neal Bhatia MD, David Pariser MD, Ping-Yu Liu PhD, Deepak Chadha MS, MBA, Patricia Walker MD, PhD (First Publication: June 2020)
Background: Primary axillary hyperhidrosis has limited noninvasive, effective, and well-tolerated treatment options. |Objective:To evaluate the topical treatment of axillary hyperhidrosis with the novel anticholinergic sofpironium bromide.
Histological Analysis of the Effect of ATX-101 (Deoxycholic Acid Injection) on Subcutaneous Fat: Results From a Phase 1 Open-Label Study.
Patricia S. Walker, Daniel R. Lee, Bryant A. Toth, Beta Bowen | Medicine | Dermatologic surgery : official publication for… | 2019 (First Publication: 1 February 2019)
BACKGROUND ATX-101 is approved for submental fat reduction. OBJECTIVE To characterize the histological effect of ATX-101 injection into subcutaneous fat. METHODS This Phase 1 open-label study…
Hyperhidrosis: an update on prevalence and severity in the United States.
Doolittle, James & Walker, Patricia & Mills, Thomas & Thurston, Jane. (2016). Archives of Dermatological Research.
Current published estimates of the prevalence of hyperhidrosis in the United States are outdated and underestimate the true prevalence of the condition. The objectives of this study are to provide an updated estimate of the prevalence of hyperhidrosis in the US population and to further assess the severity and impact of sweating on those affected by the condition…
The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.
Brandon M. Kirsch, Laurie B Burke, Jeremy Hobart, David Angulo, Patricia S. Walker | Medicine | Journal of drugs in dermatology : JDD | 2018 (First Publication: 28 March 2018)
INTRODUCTION Patients with primary axillary hyperhidrosis (AHH) suffer from a variety of symptoms. Improved patient-reported outcome (PRO) measures are needed to better assess and categorize the…
ATX-101 for reduction of submental fat: A phase III randomized controlled trial.
Shannon Humphrey, Jonathan R Sykes, +6 authors Frederick C. Beddingfield | Medicine | Journal of the American Academy of Dermatology | 2016 (First Publication: 1 October 2016)
BACKGROUND ATX-101, an injectable form of deoxycholic acid, causes adipocytolysis when injected subcutaneously into fat. OBJECTIVE We sought to evaluate the efficacy and safety of ATX-101. …
A Pooled Analysis of the Safety and Efficacy Results of the Multicenter, Double-Blind, Randomized, Placebo-Controlled Phase 3 REFINE-1 and REFINE-2 Trials of ATX-101, a Submental Contouring…
Steven H Dayan, Derek H. T. Jones, +7 authors Frederick C. Beddingfield | Medicine | 2014 (First Publication: 1 October 2014)
An interrater and intrarater reliability study of 3 photographic scales for the classification of perioral aesthetic features.
Joel L Cohen, Jane E Thomas, +6 authors Ramana Yalamanchili | Medicine | Dermatologic surgery : official publication for… | 2014 (First Publication: 1 June 2014)
BACKGROUND Validated aesthetic rating scales for the perioral area provide objective evaluations for clinical trials and practice. OBJECTIVE To confirm the reliability of 3 scales for evaluating…
Natrelle saline-filled breast implants: a prospective 10-year study.
Patricia S. Walker, Beth Walls, Diane Murphy | Medicine | Aesthetic surgery journal | 2009
BACKGROUND Natrelle saline-filled breast implants (Allergan, Santa Barbara, CA) are in widespread use in the United States for both breast augmentation and reconstruction. The primary safety concerns…
Juvéderm injectable gel: a multicenter, double-blind, randomized study of safety and effectiveness.
Mark A. Pinsky, Jane Anne Thomas, Diane Murphy, Patricia S. Walker | Medicine | Aesthetic surgery journal | 2008
BACKGROUND A high concentration of crosslinked hyaluronic acid (HA) in a smooth, malleable formulation is the hallmark of the new Juvéderm dermal fillers. OBJECTIVE To determine the long-term…
Comparison of smooth-gel hyaluronic acid dermal fillers with cross-linked bovine collagen: a multicenter, double-masked, randomized, within-subject study.
L. Baumann, Ava T Shamban, +4 authors Patricia S. Walker | Medicine | Dermatologic surgery : official publication for… | 2007 (First Publication: 1 December 2007)
BACKGROUND A new family of next-generation non-animal hyaluronic acid (HA) dermal fillers was approved by the FDA in June 2006. Compared with other HA fillers available in the United States at the…
Inamed silicone breast implant core study results at 6 years.
Scott L. Spear, Diane Murphy, Araceli Slicton, Patricia S. Walker | Medicine | Plastic and reconstructive surgery | 2007 (First Publication: 1 December 2007)
BACKGROUND Silicone gel-filled breast implants were developed in 1962 but did not fall under the auspices of the U.S. Food and Drug Administration until 1976 and were not classified as class III…
The safety of silicone gel-filled breast implants: a review of the epidemiologic evidence.
Joseph K. Mclaughlin, Loren Lipworth, Diane Murphy, Patricia S. Walker | Medicine | Annals of plastic surgery | 2007 (First Publication: 1 November 2007)
Few implantable medical devices have been studied for their safety more extensively than silicone gel-filled breast implants. We summarize the epidemiologic evidence on the safety of breast implants,…
Microscopy analysis of breast implant rupture caused by surgical instrument damage.
Harold J. Brandon, Michael L. Taylor, Thomas E. Powell, Patricia S. Walker | Medicine | Aesthetic surgery journal | 2007 (First Publication: 1 May 2007)
BACKGROUND The mechanism of breast implant rupture has continued to be an important topic throughout the plastic surgery community and regulatory agencies, such as the US Food and Drug…
Comparison of extrusion forces of different hyaluronic acid dermal fillers: P2905
A. Tezel, Patricia S. Walker | Medicine | 2007 (First Publication: 1 February 2007)
Style 410 cohesive silicone breast implants: safety and effectiveness at 5 to 9 years after implantation.
Per Hedén, B. Boné, Diane Murphy, Araceli Slicton, Patricia S. Walker| Medicine | Plastic and reconstructive surgery | 2006 (First Publication: 1 November 2006)
BACKGROUND Inamed introduced a fourth-generation implant, the Style 410 cohesive silicone breast implant, in 1993. To date, little has been published on this implant despite its widespread use in…
Prevalence of rupture in inamed silicone breast implants.
Per Hedén, Maurizio B. Nava, +6 authors Patricia S. Walker | Medicine | Plastic and reconstructive surgery | 2006 (First Publication: 1 August 2006)
BACKGROUND Silicone breast implants have been used for decades and are arguably the most studied implantable device. However, the vast body of scientific literature has been unable to establish a…
Morphology of breast implant fold flaw failure.
Harold J. Brandon, Michael L. Taylor, Thomas E. Powell, Patricia S. Walker | Medicine| Journal of long-term effects of medical implants | 2006
The percent of modern silicone gel breast implants that fail due to shell rupture is quite low, amounting to less than 1% per year. Nonetheless, extensive retrieval and analysis studies are being…
A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage.
Sewon Kang, Gerald G. Krueger, +4 authors John R. Gibson | Medicine | Journal of the American Academy of Dermatology | 2005 (First Publication: 1 February 2005)
BACKGROUND Previous studies indicate that tazarotene is efficacious in reducing signs of photodamage. Objective We sought to confirm the efficacy and tolerability of tazarotene 0.1% cream in the…
Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, multicentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin.
Lawrence A Machtinger, Kays H. Kaidbey, +7 authors Patricia S. Walker | Medicine | The British journal of dermatology | 2004 (First Publication: 1 December 2004)
BACKGROUND Topical tazarotene has been shown to offer efficacy in ameliorating multiple effects of photodamage. OBJECTIVES To evaluate the histological effects of tazarotene cream on photodamaged…
Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials.
Alan R. Shalita, Diane S. Berson, +5 authors John R. Gibson | Medicine | Clinical therapeutics | 2004 (First Publication: 1 November 2004)
BACKGROUND Topical retinoids are one of the most effective classes of topical drugs used to treat acne vulgaris. The effects of the gel formulation of the topical retinoid tazarotene have been widely…
Tazarotene Does Not Affect the Pharmacokinetics and Efficacy of a Norethindrone/Ethinylestradiol Oral Contraceptive
Zhiling Yu, D. Y. Yu, Patricia S. Walker, Diane D.-S. Tang-Liu | Medicine | Clinical pharmacokinetics | 2004 (First Publication: 1 August 2004)
Objective: To determine the pharmacokinetic and pharmacodynamic interaction between oral tazarotene and an oral contraceptive containing norethindrone 1mg and ethinylestradiol 0.035mg (Ortho-Novum®…
An open-label extension study evaluating the efficacy and safety of oral tazarotene in plaque psoriasis
Kim A. Papp, Frederick C. Beddingfield, Susan Manrow, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Photographic documentation of the efficacy of oral tazarotene in nodulocystic acne
James J. Leyden, Deborah A. Lew-Kaya, Patricia S. Walker | Medicine| 2004 (First Publication: 1 March 2004)
The clinical potential of oral tazarotene for nodulocystic acne has been assessed in two dose-ranging studies that involved 277 patients and evaluated once-daily doses of 0.4 mg to 2.8 mg (for 12… Continue Reading
A long-term, open-label study of the safety and efficacy of oral tazarotene in moderate to very severe plaque psoriasis
Alan Menter, Deborah A. Lew-Kaya, Frederick C. Beddingfield, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Oral tazarotene reduces comedones
Jerry K.L. Tan, Deborah A. Lew-Kaya, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Simple and convenient dosing is possible with oral tazarotene
Dale Yu, Edward Lee, Patricia S. Walker, Diane D.-S. Tang-Liu | Medicine | 2004 (First Publication: 1 March 2004)
Duration of clinical improvement with oral tazarotene in plaque psoriasis
John Koo, N. Lowe, John Sefton, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Oral tazarotene has been shown to be highly effective for the treatment of moderate to very severe plaque psoriasis, significantly improving plaque elevation, scaling, erythema, and percentage body…
Quality of life effect of oral tazarotene in patients with moderate to severe psoriasis as measured by the 12-item psoriasis quality of life questionnaire (PQOL-12)
John Y. M. Koo, Jonathan W. Kowalski, Lyn Guenther, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
QUALITY OF LIFE EFFECT OF ORAL TAZAROTENE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS AS MEASURED BY THE 12-ITEM PSORIASIS QUALITY OF LIFE QUESTIONNAIRE (PQOL-12) John YM Koo, MD, UCSF Psoriasis…
Safety of oral tazarotene in nodulocystic acne
Nick Lowe, Deborah A. Lew-Kaya, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Oral tazarotene improves scalp psoriasis
Emil A. Tanghetti, Yves P Poulin, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Oral tazarotene was generally well tolerated. The only adverse events occurring during the treatment period in a significantly greater percentage of patients treated with oral tazarotene than…
Safety of oral tazarotene in moderate to severe plaque psoriasis
Patricia S. Walker, Alice Bendix Gottlieb, Lyn Guenther, Alan Menter | Medicine | 2004 (First Publication: 1 March 2004)
Oral tazarotene and difficult-to-treat psoriatic lesions
Sewon Kang, Alan Menter, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Evaluating psoriasis severity: limitations of the PASI and advantages of the overall lesional assessment
Deborah A. Lew-Kaya, John C. Lue, John Sefton, Patricia S. Walker | Medicine | 2004 (First Publication: 1 March 2004)
Evaluating psoriasis severity: limitations of the PASI and advantages of the overall lesional assessment 1 1 All authors are employees of Allergan, Inc.
Deborah A. Lew-Kaya, John C. Lue, John Sefton, Patricia S. Walker | Medicine | 2004
Pharmacokinetics of Tazarotene Cream 0.1% After a Single Dose and After Repeat Topical Applications at Clinical or Exaggerated Application Rates in Patients with Acne Vulgaris or Photodamaged Skin
Zhiling Yu, John Sefton, Deborah A. Lew-Kaya, Patricia S. Walker, D. Y. Yu, Diane D.-S. Tang-Liu | Medicine | Clinical pharmacokinetics | 2003 (First Publication: 1 August 2003)
Abstract Objective: To evaluate the safety and pharmacokinetics of tazarotene cream 0.1% under standard (face only) or exaggerated (15% body surface area, including the face) application conditions…
Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily…
Gerald D. Weinstein, John Y. M. Koo, +7 authors Patricia S. Walker | Medicine | Journal of the American Academy of Dermatology | 2003 (First Publication: 1 May 2003)
BACKGROUND Tazarotene in a gel formulation is widely used in the treatment of psoriasis. OBJECTIVE To determine the efficacy and safety of tazarotene 0.1% and 0.05% creams in the treatment of…
Efficacy of 0.1% tazarotene cream for the treatment of photodamage: a 12-month multicenter, randomized trial.
Tania j. Phillips, Alice Bendix Gottlieb, +5 authors John R. Gibson | Medicine | Archives of dermatology | 2002 (First Publication: 1 November 2002)
OBJECTIVE To determine the efficacy and safety of 0.1% tazarotene cream for the treatment of photodamage. DESIGN A 24-week multicenter, double-blind, randomized, vehicle-controlled intervention…
Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams…
Sewon Kang, James J. Leyden, +9 authors John R. Gibson | Medicine | Archives of dermatology | 2001 (First Publication: 1 December 2001)
OBJECTIVE To assess the safety and efficacy of 4 concentrations of tazarotene cream in the treatment of facial photodamage. DESIGN Prospective weekly multicenter, investigator-masked, randomized,…
Activation of skin-derived dendritic cells by CpG-containing oligodeoxynucleotides(ODN) with immunostimulatory activity
Patricia S. Walker, Thilo Jakob, Arthur M. Krieg, Mark C. Udey, Jonathan C. Vogel | Biology | 1998 (First Publication: 1 March 1998)
Activation of Cutaneous Dendritic Cells by CpG-Containing Oligodeoxynucleotides: A Role for Dendritic Cells in the Augmentation of Th1 Responses by Immunostimulatory DNA
Thilo Jakob, Patricia S. Walker, Arthur M. Krieg, Mark C. Udey, Jonathan C. Vogel | 1998
Cytokine gene expression in epidermis with biological effects following injection of naked DNA
Ulrich R. Hengge, Edward Fremont Chan, Ruth Ann Foster, Patricia S. Walker, Jonathan C. Vogel | Biology, Medicine | Nature Genetics | 1995 (First Publication: 1 June 1995)
The epidermis is readily accessible for genetic manipulation and is easily monitored. Using pig skin because it is very similar to human skin morphologically, we have developed a method to…
Rudimentary meningocele presenting with a scalp hair tuft. Report of two cases.
Mary Seabury Stone, Patricia S. Walker, Carl Kennard | Medicine | Archives of dermatology | 1994 (First Publication: 1 June 1994)
BACKGROUND Rudimentary meningoceles represent a developmental anomaly in which meningothelial elements are found in the skin. The majority of rudimentary meningoceles occur on the scalp over the…